Previous Close | 0.5994 |
Open | 0.6250 |
Bid | 0.6104 x 3100 |
Ask | 0.6200 x 800 |
Day's Range | 0.6000 - 0.6349 |
52 Week Range | 0.5600 - 1.4000 |
Volume | |
Avg. Volume | 76,035 |
Market Cap | 26.627M |
Beta (5Y Monthly) | 1.03 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3600 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30th June 2022 (Q4 FY22).
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first patient has been dosed in the Company's Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.